Primcogent Solutions introduces low level laser therapy for onychomycosis

Primcogent Solutions - supplier of the revolutionary ZERONA non-invasive body contouring technology in North America and Western Europe - has announced the launch of Lunula Laser, a clinically proven, low level laser therapy for onychomycosis, for distribution exclusively in Europe. Lunula Laser brings new hope to people suffering from fungal nail infections, providing a completely safe, pain-free treatment of onychomycosis in just two 12-minute treatments.

Manufactured by Erchonia, Lunula Laser is based on Low Level Laser Technology (LLLT) and provides effective treatment of onychomycosis without the risks and harmful side effects of oral medication, or the pain and recovery time associated with other laser treatments. It combines two different wavelength lasers - one at 405 nm for direct fungicidal activity and one at 635 nm to stimulate a natural immune response - to provide effective clearing of the nail bed within three months. In a recent study of 105 toenails, clinicians observed a mean percentage change in clear nail bed of 30.4 percent, or 5 mm. Furthermore, 62 percent of toenails treated achieved at least a 25 percent increase in clear nail after 3 months, thus validating the use of Lunula Laser to target onychomycosis.

The Lunula Laser has been specifically designed for use by physicians and their staff, requiring very little set-up time and no operator intervention, creating a complete walk-away treatment thanks to preset dosage times and output energies. This innovative therapy provides effective relief for patients after just two treatments, alleviating the pain and embarrassment of unsightly nail fungus by restoring growth of clear, healthy nails.